Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin
Status:
Completed
Trial end date:
2006-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safe and effective dose of Argatroban for
prophylaxis and/or treatment of thrombosis in pediatric patients with current or previous
diagnosis of heparin-induced thrombocytopenia (HIT) and thrombosis syndrome (HITTS), or who
in the opinion of the investigator require alternative anticoagulation due to an underlying
condition.